Caladrius Biosciences Inc (NASDAQ:CLBS) Given Average Recommendation of “Buy” by Brokerages

Shares of Caladrius Biosciences Inc (NASDAQ:CLBS) have received a consensus rating of “Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $10.42.

CLBS has been the topic of several recent research reports. ValuEngine upgraded shares of Caladrius Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded shares of Caladrius Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 14th.

NASDAQ:CLBS traded up $0.06 during trading hours on Tuesday, reaching $2.16. 9,400 shares of the company were exchanged, compared to its average volume of 29,088. The stock has a 50 day simple moving average of $2.35 and a 200 day simple moving average of $2.62. Caladrius Biosciences has a 52-week low of $2.00 and a 52-week high of $5.44. The firm has a market cap of $22.26 million, a price-to-earnings ratio of -1.29 and a beta of 1.46.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Caladrius Biosciences (NASDAQ:CLBS) last posted its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.04). On average, analysts forecast that Caladrius Biosciences will post -1.54 EPS for the current fiscal year.

A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc. raised its stake in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) by 7.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 207,973 shares of the biotechnology company’s stock after buying an additional 14,740 shares during the period. Vanguard Group Inc. owned approximately 2.00% of Caladrius Biosciences worth $474,000 as of its most recent SEC filing. 8.03% of the stock is owned by institutional investors.

About Caladrius Biosciences

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

See Also: What are momentum indicators and what do they show?

Leave a Reply

Your email address will not be published. Required fields are marked *